Login / Signup

European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.

Liese BarbierSteven R A SimoensArnold G VultoIsabelle Huys
Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)
This study proposes a number of strategic, practical, and overarching recommendations to support healthcare professionals and inform decision makers to improve the clinical use of biosimilars and the willingness of stakeholders to use them. The proposed solutions to fully realise the potential of biosimilars for healthcare systems and patients include developing practical switch guidance, being transparent about the gains from biosimilar use (and how savings are allocated), and developing a combination of non-tangible and tangible incentives for involved stakeholders.
Keyphrases
  • clinical practice
  • healthcare
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • smoking cessation
  • health information
  • antiretroviral therapy